Atomo NewsGet the app

Get the latest Science News and Discoveries

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC - EurekAlert!


Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of Chemotherapy

Chemotherapy

Photo of FLAURA2 trial

FLAURA2 trial

Photo of overall survival

overall survival

Related news:

News photo

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!

News photo

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!

News photo

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC - EurekAlert!

« Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!
Innovation Crossroads companies join forces, awarded U.S. Air Force contract - EurekAlert! »